PURPOSE: A fibrotic focus, the scar-like area found in the center of an invasive breast tumor, is a prognostic parameter associated with an expansive growth pattern, hypoxia, and (lymph)angiogenesis. Little is known about the molecular pathways involved. EXPERIMENTAL DESIGN: Sixty-five patients were selected of whom microarray data of the tumor and H&E slides for histologic analysis were available. The growth pattern and the presence and size of a fibrotic focus were assessed. Differences in biological pathways were identified with global testing. The correlations of growth pattern and fibrotic focus with common breast cancer signatures and with clinicopathologic variables and survival were investigated. RESULTS: Tumors with a large fibrotic focus showed activation of Ras signaling and of the hypoxia-inducible factor-1alpha pathway. Furthermore, unsupervised hierarchical cluster analysis with hypoxia- and (lymph)angiogenesis-related genes showed that hypoxia-inducible factor-1alpha, vascular endothelial growth factor A, and carbonic anhydrase 9 were overexpressed. The presence of a fibrotic focus, especially a large fibrotic focus, was associated with the basal-like subtype (P = 0.009), an activated wound-healing signature (P = 0.06), and a poor-prognosis 76-gene signature (P = 0.004). The presence of a fibrotic focus (P = 0.02) and especially of a large fibrotic focus (P = 0.004) was also associated with early development of distant metastasis. CONCLUSIONS: Our results sustain the hypothesis that hypoxia-driven angiogenesis is essential in the biology of a fibrotic focus. Ras and Akt might play a role as downstream modulators. Our data furthermore suggest that vascular endothelial growth factor A does not only drive angiogenesis but also lymphangiogenesis in tumors with a fibrotic focus. Our data also show an association between the presence of a fibrotic focus and infaust molecular signatures.
PURPOSE: A fibrotic focus, the scar-like area found in the center of an invasive breast tumor, is a prognostic parameter associated with an expansive growth pattern, hypoxia, and (lymph)angiogenesis. Little is known about the molecular pathways involved. EXPERIMENTAL DESIGN: Sixty-five patients were selected of whom microarray data of the tumor and H&E slides for histologic analysis were available. The growth pattern and the presence and size of a fibrotic focus were assessed. Differences in biological pathways were identified with global testing. The correlations of growth pattern and fibrotic focus with common breast cancer signatures and with clinicopathologic variables and survival were investigated. RESULTS:Tumors with a large fibrotic focus showed activation of Ras signaling and of the hypoxia-inducible factor-1alpha pathway. Furthermore, unsupervised hierarchical cluster analysis with hypoxia- and (lymph)angiogenesis-related genes showed that hypoxia-inducible factor-1alpha, vascular endothelial growth factor A, and carbonic anhydrase 9 were overexpressed. The presence of a fibrotic focus, especially a large fibrotic focus, was associated with the basal-like subtype (P = 0.009), an activated wound-healing signature (P = 0.06), and a poor-prognosis 76-gene signature (P = 0.004). The presence of a fibrotic focus (P = 0.02) and especially of a large fibrotic focus (P = 0.004) was also associated with early development of distant metastasis. CONCLUSIONS: Our results sustain the hypothesis that hypoxia-driven angiogenesis is essential in the biology of a fibrotic focus. Ras and Akt might play a role as downstream modulators. Our data furthermore suggest that vascular endothelial growth factor A does not only drive angiogenesis but also lymphangiogenesis in tumors with a fibrotic focus. Our data also show an association between the presence of a fibrotic focus and infaust molecular signatures.
Authors: Agnieszka K Witkiewicz; Abhijit Dasgupta; Sara Sammons; Ozlem Er; Magdalena B Potoczek; Fran Guiles; Federica Sotgia; Jonathan R Brody; Edith P Mitchell; Michael P Lisanti Journal: Cancer Biol Ther Date: 2010-07-07 Impact factor: 4.742
Authors: Dalit Barkan; Lara H El Touny; Aleksandra M Michalowski; Jane Ann Smith; Isabel Chu; Anne Sally Davis; Joshua D Webster; Shelley Hoover; R Mark Simpson; Jack Gauldie; Jeffrey E Green Journal: Cancer Res Date: 2010-06-22 Impact factor: 12.701
Authors: Steven T Proulx; Paola Luciani; Stefanie Derzsi; Matthias Rinderknecht; Viviane Mumprecht; Jean-Christophe Leroux; Michael Detmar Journal: Cancer Res Date: 2010-09-07 Impact factor: 12.701
Authors: Agnieszka K Witkiewicz; Jessica Kline; Maria Queenan; Jonathan R Brody; Aristotelis Tsirigos; Erhan Bilal; Stephanos Pavlides; Adam Ertel; Federica Sotgia; Michael P Lisanti Journal: Cell Cycle Date: 2011-06-01 Impact factor: 4.534
Authors: Eugenio Maiorano; Meredith M Regan; Giuseppe Viale; Mauro G Mastropasqua; Marco Colleoni; Monica Castiglione-Gertsch; Karen N Price; Richard D Gelber; Aron Goldhirsch; Alan S Coates Journal: Breast Cancer Res Treat Date: 2009-03-12 Impact factor: 4.872
Authors: Agnieszka K Witkiewicz; Abhijit Dasgupta; Federica Sotgia; Isabelle Mercier; Richard G Pestell; Michael Sabel; Celina G Kleer; Jonathan R Brody; Michael P Lisanti Journal: Am J Pathol Date: 2009-05-01 Impact factor: 4.307
Authors: Ying Chen; Tor A Klingen; Elisabeth Wik; Hans Aas; Einar Vigeland; Knut Liestøl; Øystein Garred; Jan Mæhlen; Lars A Akslen; Jon Lømo Journal: Diagn Pathol Date: 2014-12-19 Impact factor: 2.644
Authors: Xue B Holdman; Thomas Welte; Kimal Rajapakshe; Adam Pond; Cristian Coarfa; Qianxing Mo; Shixia Huang; Susan G Hilsenbeck; Dean P Edwards; Xiang Zhang; Jeffrey M Rosen Journal: Breast Cancer Res Date: 2015-11-18 Impact factor: 6.466
Authors: Z L Teo; E Provenzano; G S Dite; D J Park; C Apicella; S D Sawyer; P A James; G Mitchell; A H Trainer; G J Lindeman; K Shackleton; L Cicciarelli; S S Buys; I L Andrulis; A M Mulligan; G Glendon; E M John; M B Terry; M Daly; F A Odefrey; T Nguyen-Dumont; G G Giles; J G Dowty; I Winship; D E Goldgar; J L Hopper; M C Southey Journal: Br J Cancer Date: 2013-06-20 Impact factor: 7.640